1. Novel 2-phenyl-3-(Pyridin-2-yl) thiazolidin-4-one derivatives as potent inhibitors for proliferation of osteosarcoma cells in vitro and in vivo
- Author
-
Li Niu, Tong Zhu, Dan Ni, Qinghua Wei, Longlong Song, Yuqiao Han, Rou Pi, Yaqi Deng, Wangyujing Han, Yun Zhao, Zhengli Luo, Donghui Sun, Suzhen Dong, Shunying Liu, and Zi Li
- Subjects
Male ,Cell Survival ,Pyridines ,Phenotypic screening ,Mice, Nude ,Antineoplastic Agents ,Bone Neoplasms ,chemistry.chemical_compound ,Mice ,Structure-Activity Relationship ,Pharmacokinetics ,In vivo ,Cell Line, Tumor ,Drug Discovery ,medicine ,Potency ,Animals ,Humans ,Cell Proliferation ,Pharmacology ,Mice, Inbred BALB C ,Mice, Inbred ICR ,Osteosarcoma ,Dose-Response Relationship, Drug ,Molecular Structure ,Chemistry ,Organic Chemistry ,Cell migration ,General Medicine ,Neoplasms, Experimental ,medicine.disease ,In vitro ,Cancer research ,Thiazolidines ,Female ,Drug Screening Assays, Antitumor ,Lead compound - Abstract
Due to unknown pathogenesis and unidentified drug target, no drug for the treatment of osteosarcoma (OS) has been launched to the market. Herein, thiazolidinone 1a was discovered as a hit compound by phenotypic screening with an in-house patrimonial collection of structural diversity. The following SAR (Structure-Activity Relationship) study affords the final water-soluble lead compound (R)-8i as a potential inhibitor for the proliferation of OS cells by the modulation of solubility of the compounds with remarkable cellular potency (IC50 = 21.9 nM for MNNG/HOS cells) and in vivo efficacy (52.9% inhibition OS growth in mice), as well as pharmacokinetic properties. (R)-8i also significantly suppresses OS cell migration in vitro and showed to be well-tolerated. Our preliminary investigation shows that the effects of (R)-8i are not dependent on p53 and myoferlin (MYOF). These results suggest that (R)-8i might be a potential drug candidate for OS treatment.
- Published
- 2021